Microsoft Cloud Authors: Elizabeth White, Yeshim Deniz, Serafima Al, Janakiram MSV, John Katrick

News Feed Item

Eventide Asset Management Launches the Eventide Healthcare & Life Sciences Fund

BOSTON, MA -- (Marketwire) -- 01/11/13 -- Eventide Asset Management, LLC, a Boston-based investment advisory firm that is committed to biblically responsible investing, has launched the Eventide Healthcare & Life Sciences Fund (NASDAQ: ETGLX) on December 27, 2012. The Eventide Healthcare & Life Sciences Fund is a non-diversified fund that uses bottom-up fundamental research to find healthcare and life sciences companies with the potential to appreciate in value as positive data is released regarding clinical trials and FDA feedback, and market acceptance of products. The Fund has four share classes: ETNHX (N), ETIHX, (I), ETAHX (A), and ETCHX (C).

Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. These companies include smaller development-stage companies.

According to lead portfolio manager Finny Kuruvilla, MD PhD, despite revolutionary advances in biology, we've only witnessed its nascency. Dr. Kuruvilla commented: "There is what I call an 'opportunity vacuum' for health and life sciences, as scientific understanding significantly outpaces approved treatments it the marketplace. This highly addressable pipeline, combined with the deepening pockets and growing appetites of large biopharma, promise exciting investment opportunities well into the future." In support of this investment thesis, Kuruvilla cited a recent report from Morgan Stanley and Thomson Reuters indicating a widening gap between the free cash flow of large biopharma companies and the entire US smid-cap biotech market capitalization. In other words, "Large biopharma has more money to spend than there are opportunities to buy, and the gap is widening, not closing," said Kuruvilla.

In addition to a compelling investment thesis, investors should be attracted to the Eventide Healthcare & Life Sciences Fund because of the expectation of diversification benefits in broad investment portfolios. According to the Morgan Stanley Strategy team, biotechnology has the most non-correlation of any industry group. This is especially true of small-cap biotechnology companies, where risks are typically more tied to company-specific events -- such as, clinical trial data releases and FDA feedback -- than to macro-economic forces.

The Eventide Healthcare & Life Sciences Fund will be managed by Eventide's lead portfolio manager, Finny Kuruvilla, MD PhD. Dr. Kuruvilla has been primarily responsible for the day-to-day management of the Eventide Gilead Fund since its inception on July 8, 2008. The Eventide Gilead Fund is a diversified mutual fund that primarily invests in small and mid-cap growth companies. Under his leadership, the Eventide Gilead Fund's no-load class (NASDAQ: ETGLX) has returned an annualized performance of 11.08% from July 8, 2008 to December 31, 2012 net of all fees, while the S&P 500 has returned 4.88% and the Russell Midcap Growth Index 6.00%. The fund has garnered numerous awards from the Wall Street Journal for its outperformance since inception in July 2008.

Along with his role as portfolio manager at Eventide, Dr. Kuruvilla also serves as Principal at Clarus Ventures, a health care venture capital firm with $1.2 billion under management. He represents Clarus on the Board of Directors of Nanostring, and is also a Board Observer for Catabasis, Lycera, Tetralogic, and Virdante. He has cared for adult and pediatric patients suffering from a wide variety of hematologic, oncologic, and autoimmune disorders at the Brigham & Women's Hospital, Children's Hospital Boston, the Dana Farber Cancer Institute, the Beth Israel Deaconess Hospital, and the Massachusetts General Hospital. He has also conducted research at the Broad Institute of Harvard and MIT in medical genetics from 2006 to 2008. Dr. Kuruvilla did his residency at the Brigham & Women's Hospital from 2003 to 2006 and his fellowship in transfusion medicine at Harvard Medical School from 2006 to 2007. He received his MD from Harvard Medical School, his PhD in chemistry and chemical biology from Harvard University, his master's degree in electrical engineering and computer science from MIT, and his bachelor's degree from Caltech.

The following table shows the Gilead Fund's performance since inception:

                                                      3 year     inception
 As of 12/31/2012              YTD return  1 year   annualized  (7/08/2008)
                                           return     return     annualized
Eventide Gilead Fund*            18.15%    18.15%     11.95%       11.08%
S&P 500 Total Return Index       16.00%    16.00%     10.87%       4.88%
Russell Mid-Cap Growth Total
Return Index                     15.81%    15.81%     12.91%       6.00%

Eventide Gilead Fund expenses ratios: Gross Expenses 2.05%; Net Expenses 1.64%. The advisor has agreed to maintain the Fund's total annual operating expenses at 1.64% until at least October 31, 2013. Three-year and inception returns are annualized. The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor's shares, when redeemed, may be worth more or less than their original cost. Please review the fund's prospectus for more information regarding the fund's fees and expenses. Performance shown is for No-load Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836).

The S&P 500 is an index created by Standard & Poor's Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. Neither index is an investment product available for purchase.

Mutual Funds involve risk including the possible loss of principal. Both the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds' ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The Eventide Healthcare & Life Sciences fund is non-diversified and its performance largely depends on the overall condition of the healthcare sector. The Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund can both have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The fund can have risk associated with a higher portfolio turnover which could result in higher transactional costs.

An investor should consider the Fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about the Eventide Gilead Fund can be found in the Fund's prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the fund, toll free at 877-771- EVEN (3836). You can also obtain a prospectus at www.eventidefunds.com. The Eventide Gilead Fund is distributed by Northern Lights Distributors, LLC, which is not affiliated with Eventide Asset Management, LLC.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Fund Contact:
Robin John
877-771-EVEN (3836), x55

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

@ThingsExpo Stories
"There's plenty of bandwidth out there but it's never in the right place. So what Cedexis does is uses data to work out the best pathways to get data from the origin to the person who wants to get it," explained Simon Jones, Evangelist and Head of Marketing at Cedexis, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Digital Transformation and Disruption, Amazon Style - What You Can Learn. Chris Kocher is a co-founder of Grey Heron, a management and strategic marketing consulting firm. He has 25+ years in both strategic and hands-on operating experience helping executives and investors build revenues and shareholder value. He has consulted with over 130 companies on innovating with new business models, product strategies and monetization. Chris has held management positions at HP and Symantec in addition to ...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities - ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups.
In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect at GE, and Ibrahim Gokcen, who leads GE's advanced IoT analytics, focused on the Internet of Things / Industrial Internet and how to make it operational for business end-users. Learn about the challenges posed by machine and sensor data and how to marry it with enterprise data. They also discussed the tips and tricks to provide the Industrial Internet as an end-user consumable service using Big Data Analytics and Industrial C...
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
When talking IoT we often focus on the devices, the sensors, the hardware itself. The new smart appliances, the new smart or self-driving cars (which are amalgamations of many ‘things'). When we are looking at the world of IoT, we should take a step back, look at the big picture. What value are these devices providing. IoT is not about the devices, its about the data consumed and generated. The devices are tools, mechanisms, conduits. This paper discusses the considerations when dealing with the...
DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term.
To Really Work for Enterprises, MultiCloud Adoption Requires Far Better and Inclusive Cloud Monitoring and Cost Management … But How? Overwhelmingly, even as enterprises have adopted cloud computing and are expanding to multi-cloud computing, IT leaders remain concerned about how to monitor, manage and control costs across hybrid and multi-cloud deployments. It’s clear that traditional IT monitoring and management approaches, designed after all for on-premises data centers, are falling short in ...
With privacy often voiced as the primary concern when using cloud based services, SyncriBox was designed to ensure that the software remains completely under the customer's control. Having both the source and destination files remain under the user?s control, there are no privacy or security issues. Since files are synchronized using Syncrify Server, no third party ever sees these files.
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
In his session at 21st Cloud Expo, Carl J. Levine, Senior Technical Evangelist for NS1, will objectively discuss how DNS is used to solve Digital Transformation challenges in large SaaS applications, CDNs, AdTech platforms, and other demanding use cases. Carl J. Levine is the Senior Technical Evangelist for NS1. A veteran of the Internet Infrastructure space, he has over a decade of experience with startups, networking protocols and Internet infrastructure, combined with the unique ability to it...
"Cloud Academy is an enterprise training platform for the cloud, specifically public clouds. We offer guided learning experiences on AWS, Azure, Google Cloud and all the surrounding methodologies and technologies that you need to know and your teams need to know in order to leverage the full benefits of the cloud," explained Alex Brower, VP of Marketing at Cloud Academy, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clar...
Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settlement products to hedge funds and investment banks. After, he co-founded a revenue cycle management company where he learned about Bitcoin and eventually Ethereal. Andrew's role at ConsenSys Enterprise is a mul...
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, shared examples from a wide range of industries – including en...
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Rodrigo Coutinho is part of OutSystems' founders' team and currently the Head of Product Design. He provides a cross-functional role where he supports Product Management in defining the positioning and direction of the Agile Platform, while at the same time promoting model-based development and new techniques to deliver applications in the cloud.
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of bus...
delaPlex is a global technology and software development solutions and consulting provider, deeply committed to helping companies drive growth, revenue and marketplace value. Since 2008, delaPlex's objective has been to be a trusted advisor to its clients. By redefining the outsourcing industry's business model, the innovative delaPlex Agile Business Framework brings an unmatched alliance of industry experts, across industries and functional skillsets, to clients anywhere around the world.
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
Headquartered in Plainsboro, NJ, Synametrics Technologies has provided IT professionals and computer systems developers since 1997. Based on the success of their initial product offerings (WinSQL and DeltaCopy), the company continues to create and hone innovative products that help its customers get more from their computer applications, databases and infrastructure. To date, over one million users around the world have chosen Synametrics solutions to help power their accelerated business or per...